Rocket Pharmaceuticals (RCKT) grants CMO RSUs and stock options

Rhea-AI Filing Summary

Rocket Pharmaceuticals’ Chief Medical Officer Syed Ali-aamir Rizvi received new equity awards. On February 11, 2026, he was granted 61,963 shares of common stock in the form of restricted stock units at $0 per share, bringing his directly held common stock (including RSUs) to 407,874 shares.

He was also granted a stock option covering 93,037 shares of common stock with an exercise price of $3.24 per share. For both the RSUs and the option, one-third vests on February 11, 2027, with the remainder vesting in equal quarterly installments over the following two years, contingent on continued employment.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Rizvi Syed Ali-aamir

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	93,037	$0.00	--
Grant/Award	Common Stock	61,963	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 93,037 shares (Direct); Common Stock — 407,874 shares (Direct)

Footnotes (1)

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years. This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rizvi Syed Ali-aamir

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/11/2026		A		61,963(2)	A	$0	407,874(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.24	02/11/2026		A		93,037		(3)	02/11/2036	Common Stock	93,037	$0	93,037	D

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

3. This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

	/s/ Martin Wilson, as attorney-in-fact for Syed Ali-aamir Rizvi	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rocket Pharmaceuticals (RCKT) report for its CMO?

Rocket Pharmaceuticals reported equity awards to Chief Medical Officer Syed Ali-aamir Rizvi. He received 61,963 restricted stock units and a stock option for 93,037 shares, both granted on February 11, 2026 as part of his compensation package.

How many Rocket Pharmaceuticals (RCKT) shares does the CMO hold after this Form 4?

After the reported grant, Chief Medical Officer Syed Ali-aamir Rizvi beneficially owns 407,874 shares of Rocket Pharmaceuticals common stock. This figure includes restricted stock units that convert into common shares on a one-for-one basis when they vest, as described in the filing.

What are the terms of the new stock option reported for Rocket Pharmaceuticals (RCKT) CMO?

The CMO received a stock option covering 93,037 Rocket Pharmaceuticals shares at a $3.24 exercise price. One-third becomes exercisable on February 11, 2027, with the remaining portion vesting in equal quarterly installments over two additional years, subject to continued employment.

How do the new RSUs for Rocket Pharmaceuticals (RCKT) CMO vest?

The 61,963 RSUs granted to the CMO vest over three years. One-third will fully vest on February 11, 2027, and the remaining RSUs vest in equal quarterly installments over the following two years, provided he remains employed by Rocket Pharmaceuticals.

Were Rocket Pharmaceuticals (RCKT) CMO’s new equity awards open-market purchases?

No, the transactions are classified as grants or awards, not open-market purchases. Both the 61,963 RSUs and the 93,037-share stock option were acquired at a $0 transaction price, indicating they are compensation awards rather than shares bought in the market.

What type of securities are included in Rocket Pharmaceuticals (RCKT) CMO’s holdings?

His holdings include common stock and restricted stock units that convert to common shares one-for-one. The filing specifies that total beneficial ownership of 407,874 shares incorporates these RSUs, which add to his direct equity stake upon vesting.